Blindness News and Research

RSS

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

Oraya Therapeutics, Inc. announced today that the Oraya Therapy Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD) is now available at Optegra Manchester Eye Hospital, becoming the second facility in the UK to provide the therapy.

14 Aug 2013

Research findings offer clues to the origin of retinal disorders later in life

Scientists are developing a clearer picture of how visual systems develop in mammals. The findings offer important clues to the origin of retinal disorders later in life.

9 Aug 2013

Prevalence for major eye disease is higher in people with common sleep disorder

Researchers in Taiwan have discovered that people with sleep apnea are far more likely to develop glaucoma compared to those without the sleep condition. The results of this study, which is the first to calculate the risk of the disease among people with the sleep disorder following diagnosis, is published in this month's edition of Ophthalmology, the journal of the American Academy of Ophthalmology.

8 Aug 2013

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.

6 Aug 2013

NIH-funded study of aquaporin proteins could hold clues to cataract

Researchers have achieved dynamic, atomic-scale views of a protein needed to maintain the transparency of the lens in the human eye. The work, funded in part by the National Institutes of Health, could lead to new insights and drugs for treating cataract and a variety of other health conditions.

6 Aug 2013

Study opens door to possible treatments for variety of mitochondrial diseases

By borrowing a tool from bacteria that infect plants, scientists have developed a new approach to eliminate mutated DNA inside mitochondria-the energy factories within cells. Doctors might someday use the approach to treat a variety of mitochondrial diseases, including the degenerative eye disease Leber hereditary optic neuropathy. The research, published online today in Nature Medicine, was funded by the National Eye Institute, a part of the National Institutes of Health.

5 Aug 2013

New NIH projects to target Fragile X syndrome, nicotine addiction and AMD

The National Institutes of Health has launched three innovative projects that will focus on development of therapeutics for Fragile X syndrome, nicotine addiction, and age-related macular degeneration. These projects are funded through the NIH Blueprint Neurotherapeutics Network which provides access to a variety of drug development resources.

1 Aug 2013

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca and FibroGen today announced that they have entered into a strategic collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease and end-stage renal disease.

31 Jul 2013

FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

Astellas Pharma Inc. (Tokyo:4503) (Astellas) and FibroGen, Inc. (FibroGen) announced today the initiation of a Phase 2 clinical study in Japan of ASP1517/FG-4592 for treatment of anemia associated with chronic kidney disease (CKD) in patients on dialysis.

31 Jul 2013

Study may lead to personalized treatments for mitochondrial energy disorders

Researchers have identified a master network of signaling molecules that acts like a "fuse box" to regulate the cellular effects of defective energy flow in mitochondrial respiratory chain diseases—a diverse set of difficult-to-treat genetic-based energy disorders.

25 Jul 2013

Study results suggest reexamination of biological, medical importance of X chromosome

Painstaking new analysis of the genetic sequence of the X chromosome—long perceived as the "female" counterpart to the male-associated Y chromosome—reveals that large portions of the X have evolved to play a specialized role in sperm production.

24 Jul 2013

FDA takes action to remove illegal diabetes products from market

The U.S. Food and Drug Administration is taking action to remove from the market illegal products, including some labeled as dietary supplements, that claim to mitigate, treat, cure or prevent diabetes and related complications.

24 Jul 2013

University of Florida receives RPB Sanders Construction grant

Research to Prevent Blindness has awarded a prestigious, one-time laboratory grant of $600,000 to the Department of Ophthalmology at the University of Florida, College of Medicine. The newly created laboratory will be permanently named the RPB Mildred Krahmer Sanders and William Clifford Sanders Laboratory for Vision Research.

20 Jul 2013

Brigham and Women's Hospital study examines sustained inattentional blindness in expert observers

If you were working on something at your computer and a gorilla floated across your computer screen, would you notice it? You would like to think yes, however, research shows that people often miss such events when engaged in a difficult task.

20 Jul 2013

Investigators report complete catalog of genes expressed in retina

Investigators at Massachusetts Eye and Ear and Harvard Medical School have published the most thorough description of gene expression in the human retina reported to date. In a study published today in the journal BMC Genomics, Drs. Michael Farkas, Eric Pierce and colleagues in the Ocular Genomics Institute at Mass. Eye and Ear reported a complete catalog of the genes expressed in the retina.

20 Jul 2013

IVAN study: Lucentis and Avastin effective in treating wet AMD

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness in older adults as a more expensive drug specifically formulated for this purpose.

20 Jul 2013

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Filariasis refers to a group of diseases caused by parasitic worms, which are transmitted by blood feeding insects. Two species infect the lymphatic and blood systems causing lymphatic filariasis, which in some people can lead to gross swelling of the limbs and 'elephantiasis'.

18 Jul 2013

Researchers discover new protein that encourages ‘bad’ blood vessel growth

The discovery of a protein that encourages blood vessel growth, and especially 'bad' blood vessels - the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis - has been reported in the journal Nature.

18 Jul 2013

Standardized vascular health checks may improve health and cost-effectiveness outcomes

Archimedes Inc., a healthcare modeling company, today announced the results of a two-year long collaboration with Novo Nordisk A/S, a world leader in diabetes care, which evaluated the effects of standardized vascular health checks on expected health outcomes.

17 Jul 2013

Immunization in developing countries: an interview with Dr. Jos Vandelaer, Chief of Immunization for UNICEF

Overall, worldwide, immunization programs reach around 83% of all children – this is an enormous achievement. With this level of immunization coverage, we prevent over 2 million deaths, year after year. This statistic is often forgotten or taken for granted.

11 Jul 2013

Blindness News and Research

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

Research findings offer clues to the origin of retinal disorders later in life

Prevalence for major eye disease is higher in people with common sleep disorder

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

NIH-funded study of aquaporin proteins could hold clues to cataract

Study opens door to possible treatments for variety of mitochondrial diseases

New NIH projects to target Fragile X syndrome, nicotine addiction and AMD

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

FibroGen, Astellas initiate Phase 2 study of ASP1517/FG-4592 for treatment of anemia linked with CKD

Study may lead to personalized treatments for mitochondrial energy disorders

Study results suggest reexamination of biological, medical importance of X chromosome

FDA takes action to remove illegal diabetes products from market

University of Florida receives RPB Sanders Construction grant

Brigham and Women's Hospital study examines sustained inattentional blindness in expert observers

Investigators report complete catalog of genes expressed in retina

IVAN study: Lucentis and Avastin effective in treating wet AMD

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Researchers discover new protein that encourages ‘bad’ blood vessel growth

Standardized vascular health checks may improve health and cost-effectiveness outcomes

Immunization in developing countries: an interview with Dr. Jos Vandelaer, Chief of Immunization for UNICEF

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News